Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the above-referenced patent application. Claims 30-46 have been allowed. Claims 30 and 40 are amended herein to correct typographical errors.

1. (Canceled)
2. (Canceled)
3. (Canceled).
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled).
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled).
22. (Canceled)
23. (Canceled)
24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Currently Amended) A pharmaceutical composition comprising:

(a) a therapeutically-effective amount of the compound of formula I or a pharmaceutically acceptable salts thereof, ~~wherein~~



Formula (I)

wherein R_1 is methyl, and R_2 is hydroxyl~~.~~; and

(b) a pharmaceutically-acceptable excipient.

31. (Previously Presented) The pharmaceutical composition of claim 30, wherein R_1 is methyl at position 5, and R_2 is hydroxyl at position 4.

32. (Previously Presented) The pharmaceutical composition of claim 30, wherein the composition comprises 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

33. (Previously Presented) The pharmaceutical composition of claim 30, wherein composition is formulated as a tablet, capsule, ampule or pill.

34. (Previously Presented) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for oral, intravenous, intramuscular or subcutaneous administration.

35. (Previously Presented) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for oral administration.

36. (Previously Presented) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for external administration.

37. (Previously Presented) The pharmaceutical composition of claim 30, wherein the composition is formulated as an ointment, gel, or drug-containing rubber cement.

38. (Previously Presented) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for parenteral administration.

39. (Previously Presented) The pharmaceutical composition of claim 30, wherein the composition comprises 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

40. (Currently Amended) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for slow release.

41. (Previously Presented) The pharmaceutical composition of claim 30, wherein the excipient is starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose, white bole or combinations thereof.

42. (Previously Presented) The pharmaceutical composition of claim 30, wherein the excipient is sterile water, polyethylene glycol, a nonionic surfactant, edible oil or combinations thereof.

43. (Previously Presented) The pharmaceutical composition of claim 30, further comprising an adjuvant.

44. (Previously Presented) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for administration in 2-4 separated dosages per day.

45. (Previously Presented) The pharmaceutical composition of claim 30, further comprising a flavoring agent, colorant, preservative, antioxidant, or combinations thereof.

46. (Previously Presented) The pharmaceutical composition of claim 30, further comprising vitamin E, vitamin C, butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA) or combinations thereof.